相关实验视频

Updated: May 13, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

贝克萨洛诱导的甲状腺功能低下和脂质失调;全国范围的研究

Katsunori Manaka¹, Junichiro Sato¹, Yusuke Hikima¹

¹Division of Nephrology and Endocrinology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.

Endocrine journal

|June 5, 2024

概括

贝克萨罗治疗经常导致甲状腺功能低下和脂质不良. 这项研究发现,贝克萨罗诱导的甲状腺功能低下症是快速的,并且与甘油三水平的增加有关,这表明为患者安全而采取主动的甲状腺激素替代和剂量管理.

科学领域:

内分泌学在内分泌学.
在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

贝克萨罗治疗与中央甲状腺功能低下症和脂质不良症有关.
甲状腺功能低下症是已知的失脂症的原因,但在贝克沙罗治疗期间的特定关联尚未检查.
了解这种关系对于管理贝克沙罗的不良事件至关重要.

研究的目的:

在接受贝克沙罗治疗的患者中研究甲状腺功能低下症和脂质不良症之间的关联.
分析贝克萨罗剂量和甲状腺激素水平对脂质代谢的影响.

主要方法:

在日本对294名开始服用贝克沙罗的患者进行了回顾性观察性研究.
使用Jonckheere-Terpstra和回归分析来评估贝克萨罗剂量,自由甲状腺素 (FT4),BMI和脂质变化.
监测不良事件,特别是高甘油三血症.

主要成果:

甲状腺功能低下是几乎普遍的不良事件,其中三分之二的人在一周内显示出低的自由甲状腺素 (FT4).
三糖化物水平以依赖贝克沙罗剂量的方式增加;39%的患者患有≥3级高三糖化血.
减少的FT4水平 (delta_FT4) 与增加的甘油三相关,但不是LDL-C.

结论:

贝克萨洛诱导的甲状腺功能低下是快速的,几乎是不可避免的.
过高甘油三血症与贝克沙罗剂量密切相关,与FT4水平相反相关.
建议预防性甲状腺激素替代和仔细的贝克沙罗剂量定位,以减轻严重的内分泌和代谢不良事件.

关键词:

贝克萨罗烯 (bexarotene) 是一种素.脱脂血症是什么意思脱脂血症是什么意思过高甘油三血症是什么意思甲状腺功能低下症甲状腺功能低下症

更多相关视频

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Hyperthyroidism I: Introduction

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...

Hyperthyroidism II: Pathophysiology

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...

Graves' Disease I: Introduction

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...

Graves Disease II: Pathophysiology

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...

Hypothyroidism II: Pathophysiology

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...